Oncology Business Management | Specialty

Addressing Cancer Health Disparities

April 26th 2015

Reining in the Cost of Cancer Care

April 26th 2015

Reimbursement for Oncology Treatment

April 26th 2015

Bundled Payment Models for Cancer-Related Costs

April 26th 2015

US Cancer-Related Healthcare Costs on the Rise

April 26th 2015

Mission to Treat Rural Poor Is Challenged by Merger Pressure

April 26th 2015

For Gladys Rodriguez, MD, a practicing oncologist for 24 years, the daily schedule is filled with calls to payers and hours spent at the computer typing up electronic health records.

FDA Approves Second-Line Ramucirumab for mCRC

April 24th 2015

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

FDA Updates Pomalidomide Multiple Myeloma Label

April 24th 2015

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

Crizotinib Granted Breakthrough Designation for ROS1-positive NSCLC

April 21st 2015

The FDA has granted a breakthrough therapy designation to crizotinib as a potential treatment for patients with ROS1-positive non–small cell lung cancer.

Recent FDA Approval of Ovarian Cancer Treatment Is Too Restrictive, Specialist in Gynecologic Malignancies Says in OncLive Article

April 20th 2015

The president of Medicine & Science at Cancer Treatment Centers of America and editor-in-chief of OncologyLive magazine argues the FDA's recent approval of olaparib (Lynparza) for women with BRCA-mutated advanced ovarian cancer is too restrictive and should be offered to many more patients.

Cabozantinib in RCC, Cost of Cancer Care, SGR Repeal, and More

April 17th 2015

Obama Signs SGR Repeal, Heralding New Era in Medicare Reimbursement

April 16th 2015

With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.

Senate Joins House in SGR Repeal

April 15th 2015

The Senate has joined the House of Representatives in passing legislation to repeal the Sustainable Growth Rate (SGR) formula and replace it with the Medicare Access and CHIP Reauthorization Act of 2015 (HR 2).

CMS Starts Cutting Pay for Doctors Who Don't Measure Up

April 14th 2015

The new Value-Based Payment Modifier program from the Centers for Medicare & Medicaid Services may not be high on the list of concerns for the average oncologist, but its impact could be huge.

Bankruptcy Fears Burden Cancer Patients

April 9th 2015

The possibility of going bankrupt is high on the list of concerns for 37.1% of cancer patients.

Rucaparib Receives Breakthrough Designation for BRCA-Positive Advanced Ovarian Cancer

April 6th 2015

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Internal Investigations May be Open to Court and Government Agency Scrutiny

April 4th 2015

Given a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.

ACA's High-Deductible Plans Cause Headaches, Hurt Patient Care

April 2nd 2015

The growing popularity of high-deductible health insurance plans has created a range of increasing pressures on oncologists and hematologists.

FDA Approves New Oral Formulation of Deferasirox

March 31st 2015

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.

FDA Approves Abiraterone Pre-Chemo mCRPC Label Update

March 30th 2015

The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.